Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy

Leukemia and Lymphoma

Volumn 46, Issue 10, 2005, Pages 1449-1454

  Zinzani, Peier Luigi ^a   Tani, Monica ^a   Alinari, Lapo ^a   Molinari, Anna Lia ^b   Stefoni, Vittorio ^b   Visani, Giuseppe ^c   Gentilini, Patrizia ^d   Guardigni, Luciano ^e   Fina, Mariapaola ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b AUSL Ravenna   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

^d Forli Hospital   (Italy)

^e AUSL Cesena   (Italy)

Author keywords

Anemia; Elderly aggressive NHL; Overall survival; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PNEUMOCYSTOSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ANEMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 26944485889     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500178688     Document Type: Article

References (44)

1. Balducci L, Hardy CH. Anemia of aging: a model of cancer-related anemia. Cancer Control JHLMCC 1998;5(suppl): 17-21.
2. Chatta GS, Price TH, Allen RC, Dale DC. Effects of "in vivo" recombinant methionyl human granulocyte colony stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994;84: 2923-9.
3. Lipschitz DA. Age-related decline in hemopoietic reserve capacity. Semin Oncol 1995;22(suppl 1): 3-6.
4. Moscinski LC. Hemopoiesis and aging. In Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. Amsterdam: Harwood Academic Publisher; 1999. pp 399-412.
5. Rlee MA, Segal GM, Bagby GC. The hematopietic microenvironment in the elderly: defects in IL-1-induced CSF expression in vitro. Exp Hematol 1989;17: 952-6.
6. Shank WJ, Balducci L. Recombinant hemopoietic growth factors: comparative response in younger and older subjects. J Am Geriatric Soc 1992;40: 151-154.
7. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984;32: 269-73.
8. Bastion Y, Blai JY, Divine M, Brice P, Bordessoule D, Sebban C, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment and survival. A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997;15: 2945-53.
9. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, et al. Randomized trial with or without granulocyte colony-stimulaiting factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89: 3974-8
10. Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999;94: 33-8
11. Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002;13: 1364-9.
12. Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1994;22: 483-93.
13. Gomez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, et al. Eldely patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16: 2352-8.
14. Greil R. Prognosis and management strategies of lymphatic neoplasia in the elderly. Oncology 1998;55: 189-217.
15. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson WE, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995;13: 2386-93.
16. O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993;11: 2250-7.
17. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol 1995;13: 2530-9.
18. Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, et al. CHOP is the standard regimen in patients - 70 years of age with intermediate grade and high grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative study. J Clin Oncol 1998;16: 27-34.
19. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myelogenous leukemia. Blood 1996;88: 3675-85.
20. Cleary JF. Cancer pain in the elderly. In Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. Amsterdam: Harwood Academic Publisher; 1998. pp 753-64.
21. Cleeland CS, Demetri GD, Glapsy J. Identifying hemoglobin levels for optimal Quality of Life. Results of an incremental analysis. Proceedings of the American Society of Clinical Oncology 1999;16: 574a.
22. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality of life benefit in chemotherapy patients treated with epoietin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16: 3412-25.
23. Gabrilove JL, Einhorn LH, Livingston RB. Once weekly dosing of epoietin alfa is similar to three-times weekly dosing in increasing hemoglobin and quality of life. Proceedings of the American Society of Clinical Oncology 1999;16: 574.
24. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoietin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15: 1218-34.
25. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994;21: 3-8.
26. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322: 1689-92.
27. Zucker S. Anemia in cancer. Cancer Invest 1985;3: 249-60.
28. Jelkmann W, Page H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992;50: 301-8.
29. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79: 1987-94.
30. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9: 1109-15.
31. Morrow TJ, Volpe S, Gupta S, Tannous RE, Fridman M. Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma. South Med J 2002;95: 889-96.
32. Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classifications. Cancer Res 1971;31: 1860-1.
33. Cox DR. Regression models and life-tables (with discussion). J Royal Statistical Society 1972;34: 187-220.
34. SAS Institute Inc. SAS/STAT Software: changes and enhancements through release 6.11. Scary, NC: SAS Institute Inc; 1996.
35. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4: 1470-80.
36. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989;7: 1018-26.
37. Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, et al. Prognostic factors in high and intermediate-grade non-Hodgkin's lymphoma. Br J Cancer 1989;50: 276-82.
38. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group Experience. J Clin Oncol 1986;4: 295-305.
39. Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991;67: 1389-95.
40. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991;9: 762-9.
41. Leonard RCF, Hayward RL, Prescott RJ, Wang JX. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Ann Oncol 1991;2: 655-62.
42. Bremnes RM, Bremnes Y, Donnem T. High-grade non-Hodgkin's lymphoma treated in northern Norway. Treatment, outcome and prognostic factors. Acta Oncol 1999;38: 117-24.
43. Steward WP, Crowther D, McWilliam LJ, Jones JM, Deakin DP, Todd ID, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin" lymphoma: a randomized prospective study with an assessment of prognostic factors. Cancer 1988;61: 441-7.
44. Morel P, Lepage E, Brice P, Dupriez B, D'Agay W, Fenaux P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992;7: 1078-85.